{"entity":{"id":"jur-003","kind":"drug","name":"JUR-003","aka":[],"tldr":"JUR-003 is an experimental biologic from Juri Biosciences, in phase 1 trials for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer.","summary":"JUR-003 is a biologic (T-cell engager per OnCo text; registry says only 'Biological') from Juri Biosciences, with EpimAb Biotherapeutics as partner. A biologic given intravenously in a first-in-human phase 1a/1b study in prostate cancer. Its furthest stage is phase 1, for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer and oligometastatic prostate cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1a/1b NCT07824349 recruiting (registry, first posted 17 Sep 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Juri Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07824349"},{"label":"Juri Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07824349"},{"label":"Juri Biosciences: markets.financialcontent.com","url":"https://markets.financialcontent.com/wral/article/gnwcq-2025-5-27-juri-biosciences-a-tcg-labs-soleil-portfolio-company-and-epimab-biotherapeutics-enter-into-a-worldwide-licensing-agreement-for-klk2-directed-t-cell-engager-in-metastatic-prostate-cancer"},{"label":"ClinicalTrials.gov: trials of JUR-003","url":"https://clinicaltrials.gov/search?intr=JUR-003"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate-mcrpc","prostate-mhspc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["juri-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07824349"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"JUR-003","modality":"Biologic (T-cell engager per OnCo text; registry says only 'Biological')","mechanism":"A biologic given intravenously in a first-in-human phase 1a/1b study in prostate cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jur-003/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"juri-biosciences","kind":"company","name":"Juri Biosciences","route":"/companies/juri-biosciences/"}],"trial":[{"id":"nct07824349","kind":"trial","name":"JUR-003 in Adult Patients With Metastatic Prostate Cancer","route":"/trials/nct07824349/"}]}}